Krishnansu S. Tewari, MD, discusses the excitement around immunotherapy in cervical cancer.
Krishnansu S. Tewari, MD, associate professor, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine, discusses the excitement around immunotherapy in cervical cancer.
Scientifically, it makes sense to look at these therapies in this setting, Tewari says. The mutational burden of cervical cancer is similar to other solid tumors where immunotherapy has had positive results, according to phase III findings.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More